• 1
    Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008;47:605612.
  • 2
    Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. Amer J Gastroenterol 2002;97:23912397.
    Direct Link:
  • 3
    Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007;39:293304.
  • 4
    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:20352063.
  • 5
    Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res 2010;24:14231432.
  • 6
    Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011;17:22882301.
  • 7
    Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integrative Cancer Therapies 2007;6:110119.
  • 8
    Kim NC, Graf TN, Sparacino CM, et al. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 2003;1:16841689.
  • 9
    Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem 2006;13:10551074.
  • 10
    Wagoner J, Morishima C, Graf TN, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE 2011;6:e16464.
  • 11
    Kren V, Ulrichova J, Kosina P, et al. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2000;28:15131517.
  • 12
    Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010;50:434449.
  • 13
    Lorenz D, Lucker PW, Mennicke WH, et al. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984;6:655661.
  • 14
    Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000;86:250256.
  • 15
    van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:78007806.
  • 16
    Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121:185193.
  • 17
    Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007;6:110119.
  • 18
    Saller R, Melzer J, Reichling J, et al. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed 2007;14:7080.
  • 19
    Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333338.
  • 20
    Schulz HU, Schurer M, Krumbiegel G, et al. The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung 1995;45:6164.
  • 21
    Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2008;36:19091916.
  • 22
    Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139146.
  • 23
    Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70:848855.
  • 24
    Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 2007;30:132138.
  • 25
    Sun N, Zhang X, Lu Y, et al. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med 2008;74:126132.
  • 26
    Yu JN, Zhu Y, Wang L, et al. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin 2010;31:759764.
  • 27
    Webb CB, Gustafson DL, Twedt DC. Bioavailability following oral administration of a silibinin-phosphatidylcholine complex in cats. Intern J Appl Res Vet Med 2012;10:107112.
  • 28
    Tedesco D, Tava A, Galletti S, et al. Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. J Dairy Sci 2004;87:22392247.
  • 29
    Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139143.
    Direct Link:
  • 30
    Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 2005;65:24452461.
  • 31
    Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994;27:105112.
  • 32
    Kiruthiga PV, Shafreen RB, Pandian SK, et al. Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress. Chemosphere 2007;68:15111518.
  • 33
    Valenzuela A, Guerra R, Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med 1987;53:402405.
  • 34
    Detaille D, Sanchez C, Sanz N, et al. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci 2008;82:10701076.
  • 35
    Nencini C, Giorgi G, Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007;14:129135.
  • 36
    Varzi HN, Esmailzadeh S, Morovvati H, et al. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 2007;30:477481.
  • 37
    Valenzuela A, Aspillaga M, Vial S, et al. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 1989;55:420422.
  • 38
    Webb CB, McCord KW, Twedt DC. Assessment of oxidative stress in leukocytes and granulocyte function following oral administration of a silibinin-phosphatidylcholine complex in cats. Am J Vet Res 2009;70:5762.
  • 39
    Manna SK, Mukhopadhyay A, Van NT, et al. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:68006809.
  • 40
    He Q, Kim J, Sharma RP. Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci 2004;80:335342.
  • 41
    Schumann J, Prockl J, Kiemer AK, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39:333340.
  • 42
    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749754.
  • 43
    Kang JS, Jeon YJ, Kim HM, et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Experimental Therapeutics 2002;302:138144.
  • 44
    Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009;50:11021111.
  • 45
    Au AY, Hasenwinkel JM, Frondoza CG. Silybin inhibits interleukin-1beta-induced production of pro-inflammatory mediators in canine hepatocyte cultures. J Vet Pharmacol Ther 2011;34:120129.
  • 46
    Au AY, Hasenwinkel JM, Frondoza CG. Hepatoprotective effects of S-adenosylmethionine and silybin on canine hepatocytes in vitro. J Anim Physiol Anim Nutr 2012; Feb 9. doi: 10.1111/j.1439-0396.2012.01275.x. [Epub ahead of print].
  • 47
    Kang JS, Jeon YJ, Park SK, et al. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol 2004;67:175181.
  • 48
    Kang JS, Park SK, Yang KH, et al. Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells. FEBS Lett 2003;550:8993.
  • 49
    Favari L, Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Arch Med Res 1997;28:1117.
  • 50
    Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643649.
  • 51
    Jia JD, Bauer M, Cho JJ, et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001;35:392398.
  • 52
    Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003;37:336339.
  • 53
    El-Lakkany NM, Hammam OA, El-Maadawy WH, et al. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasites Vectors 2012;5:9.
  • 54
    Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malign cell lines. Biochem Pharmacol 1986;35:538541.
  • 55
    Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem 2006;13:10551074.
  • 56
    Crocenzi FA, Pellegrino JM, Sanchez Pozzi EJ, et al. Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol 2000;59:10151022.
  • 57
    Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther 2007;6:146157.
  • 58
    Dunnick JK, Singh B, Nyska A, et al. Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol Pathol 2011;39:398409.
  • 59
    Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008;15:920.
  • 60
    Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther 2007;6:146157.
  • 61
    Vogel G, Tuchweber B, Trost W, et al. Protection by silibinin against Amanita phalloides intoxication in Beagles. Toxicol Appl Pharmacol 1984;73:355362.
  • 62
    Floersheim GL, Eberhard M, Tschumi P, et al. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharmacol 1978;46:455462.
  • 63
    Boari C, Montanari FM, Galletti GP, et al. Toxic occupational liver diseases. Therapeutic effects of silymarin. Minerva Med 1981;72:26792688.
  • 64
    Szilard S, Szentgyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung 1988;45:249256.
  • 65
    Mourelle M, Muriel P, Favari L, et al. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989;3:183191.
  • 66
    Singh D, Singh R, Singh P, Gupta RS. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats. Basic Clin Pharmacol Toxicol 2009;105:243248.
  • 67
    Campos R, Garrido A, Guerra R, et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 1989;55:417419.
  • 68
    Muthumani M, Prabu SM. Silibinin potentially protects arsenic-induced oxidative hepatic dysfunction in rats. Toxicol Mech Methods 2012;22:277288.
  • 69
    Kropacova K, Misurova E, Hakova H. Protective and therapeutic effect of silymarin on the development of latent liver damage. Radiats Biol Radioecol 1998;38:411415.
  • 70
    Ramadan LA, Roushdy HMAbu Senna GM, et al. Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res 2002;45:447454.
  • 71
    Raskovic A, Stilinovic N, Kolarovic J, et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 2011;16:86018613.
  • 72
    Muzes G, Deak G, Lang I, et al. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil 1990;131:863866.
  • 73
    van Pelt JF, Verslype C, Crabbe T, et al. Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol Alcohol 2003;38:411414.
  • 74
    Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982;17:517521.
  • 75
    Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2009;1:DOI: 10.1002/14651858.CD003620.pub3.
  • 76
    Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005;12:559567.
  • 77
    Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006;21:275280.
  • 78
    El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009;16:391400.
  • 79
    Serviddio G, Bellanti F, Giudetti AM, et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Experimental Therapeutics 2010;332:922932.
  • 80
    Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011;44:652659.
  • 81
    Salamone F, Galvano F, Cappello F, et al. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Translational Research: The Journal of Laboratory and Clinical Medicine 2012;159:477486.
  • 82
    Salamone F, Galvano F, Marino A, et al. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2012;44:334342.
  • 83
    Federico A, Trappoliere M, Tuccillo C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006;55:901902.
  • 84
    Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radical Biol Med 2012;52:16581665.
  • 85
    Loguercio C, Federico A, Trappoliere M, et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52:23872395.
  • 86
    Federico A, Niosi MVecchio Blanco CD, et al. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs 2008;13:145158.
  • 87
    Tedesco D, Domeneghini C, Sciannimanico D, et al. Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological observations. J Vet Med A Physiol Pathol Clin Med 2004;51:8589.
  • 88
    Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193203.
  • 89
    Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 2002;40:28.
  • 90
    Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105113.